Your browser doesn't support javascript.
loading
The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.
Wagner, Marie-Soleil; Arias, Raquel D; Nucatola, Deborah L.
Afiliación
  • Wagner MS; University of Montréal, Department of Obstetrics and Gynecology, St. Justine Hospital, 3175 Chemin Côte-Ste-Catherine, Montréal, QC, Canada. marie-soleil.wagner.hsj@ssss.gouv.qc.ca
Expert Opin Pharmacother ; 8(11): 1769-77, 2007 Aug.
Article en En | MEDLINE | ID: mdl-17685892
Many factors influence the effectiveness of contraceptive methods. Oral contraceptives are the second most popular contraceptive method after female sterilization in the US. A total of 25% of women do not use their oral contraceptives correctly; 30% of women do not use them consistently. Several new contraceptive methods with alternate routes of delivery and less frequent dosing are available. The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring is marketed under the name of NuvaRing. This is the only contraceptive ring approved by the FDA. The administration of steroids by the vaginal route may offer many advantages. Because of less frequent dosing, self-administration, and possibly, an improved side effect profile, the ring has the potential to increase successful use.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desogestrel / Dispositivos Anticonceptivos Femeninos / Etinilestradiol Límite: Animals / Female / Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desogestrel / Dispositivos Anticonceptivos Femeninos / Etinilestradiol Límite: Animals / Female / Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido